Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2024 | $7.00 | Buy | Rodman & Renshaw |
| 3/8/2022 | Overweight → Neutral | JP Morgan | |
| 3/4/2022 | $29.00 → $24.00 | Outperform | Raymond James |
| 1/19/2022 | $29.00 → $6.00 | Buy → Neutral | Goldman |
| 7/1/2021 | $29.00 | Outperform | Raymond James |
SC 13G - Passage BIO, Inc. (0001787297) (Subject)
SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)
SC 13G/A - Passage BIO, Inc. (0001787297) (Subject)
Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months post-treatmentDose 1 of PBFT02 was generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in multiple additional adult neurodegenerative diseases Pursuing potential partnership opportunities for clinical-stage pediatric lysosomal storage disease programs including GM1 gangliosidosisManagement to host a webcast presentation to review interim FTD data today at 8:30 a.m. ET
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF biomarkers and was able to achieve normal levels of CSF β-Gal activity and GM1 gangliosides, similar to healthy controlsDose 2 biomarker responses demonstrated durability up to 12 months after treatmentImagine-1 study participants showed initial evidence of improved survival relative to natural history dataTreated first patient at highest dose level, Dose 3, in July; initial safety and biomarker data from Dose 3 expected by mid-2024Management to host a conference call and webcast today at 8:30 a.m. ET
Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 expected in mid-2023Planned expansion of Imagine-1 study to treat patients at a higher dose; expect to dose first patient in second half of 2023Plan to report initial safety and biomarker data from Cohort 1 of global upliFT-D trial for frontotemporal dementia in the second half of 2023Ended 2022 with strong cash position; cash runway into the first half of 2025Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, March 06, 2023 (GLOBE NEW
10-Q - Passage BIO, Inc. (0001787297) (Filer)
8-K - Passage BIO, Inc. (0001787297) (Filer)
8-K - Passage BIO, Inc. (0001787297) (Filer)
Rodman & Renshaw initiated coverage of Passage BIO with a rating of Buy and set a new price target of $7.00
JP Morgan downgraded Passage Bio from Overweight to Neutral
Raymond James reiterated coverage of Passage Bio with a rating of Outperform and set a new price target of $24.00 from $29.00 previously
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $14 to $13.
Canaccord Genuity analyst Whitney Ijem reiterates Passage Bio (NASDAQ:PASG) with a Buy and maintains $14 price target.
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by strong balance sheet, with cash runway to the end of Q2 2026 PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines comp
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission
Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of PBGM01 was able to achieve healthy control levels of CSF β-Gal activity and GM1 gangliosides, with response durable up to 12 months Treated first patient at Dose 3 in Imagine-1 clinical trial in July 2023; initial safety and biomarker data from Dose 3 patients expected by mid-2024Expect to present initial safety and biomarker data from Cohort 1 in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 202
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by strong balance sheet, with cash runway to the end of Q2 2026 PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines comp
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio's website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event. About Passage Bio Passage Bio (NASDAQ:PASG) is a clinical stage genetic medicines co
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved lysosomal histopathology and reduced neuroinflammation in Grn knockout mice, and achieved widespread vector distribution throughout the nervous system in non-human primates Company delivered data during an oral presentation on Thursday, October 24 at ESGCT PHILADELPHIA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the company delivered precli
4 - Passage BIO, Inc. (0001787297) (Issuer)
4 - Passage BIO, Inc. (0001787297) (Issuer)
3 - Passage BIO, Inc. (0001787297) (Issuer)